Dr Seth Baum interviews Dr Mikhail Kosiborod about clinical trial data surrounding the possible mechanisms of action of SLGT2 inhibitors for heart failure, as well as the cardio-renal connection.
Dr Peter Jones from Houston Methodist Hospital discusses cardiovascular disease and lipids, topics in which he is speaking about during Consultant360's Cardiometabolic Risk Summit this year.
Dr Jaimin Trivedi and colleagues presented their research at the Heart Rhythm Scientific Sessions 2018 last month. Now, Dr Trivedi is answering our questions about devices in heart failure.
Dr James Januzzi from Massachusetts General Hospital discusses the new consensus statement on heart failure, biomarker testing for diagnosing heart failure, and potential future treatments.
Consultant360 recently spoke with Wesley O’Neal, MD, regarding his latest research about the link between provider specialty, anticoagulation prescription patterns, and stroke risk in patients with atrial...
<p>Dr Thomas Seck from Boehringer Ingelheim Pharmaceuticals discusses the EMPERIAL trials, which aim to expand the use of empagliflozin for heart failure.</p>
Dr Seth Baum, president of the American Society for Preventive Cardiology, welcomes you to our new podcast series and leaves clinicians with a tip for gaining access to heart failure medication.
Andrew Waxler, MD, FACC, discusses the Corus CAD test that can rule out CAD in patients presenting with possible symptoms, which would avoid unnecessary and costly procedures and guide physicians...
Calcium plaque is a known risk factor for heart attacks. In this video, Catherine Dolf discusses the results of a study that determined the predictive ability of calcium amount and density for determining a...
